Table 2. The relationship between clinicopathological factors and baseline inflammatory scores (NLR, PLR) in patients with advanced solid tumours considered for experimental treatments (Training Set).

Variable	NLR<5	NLR≥5	P	PLR<300	PLR≥300	P
Gender, M/F	24/46	14/29	0.85	28/46	10/29	0.19
Age, <65/≥65	34/36	29/14	0.05 *	37/37	26/13	0.09
ECOG PS, 0–1/≥2	61/8	24/17	<0.001 *	56/17	29/8	0.84
N of metastatic sites, <2/≥2	61/9	31/12	0.04 *	63/11	29/10	0.16
Liver metastases, absent/present	38/32	17/26	0.12	36/38	19/20	0.99
Lung metastases, absent/present	50/20	26/17	0.22	50/24	26/13	0.92
Bone metastases, absent/present	61/9	32/11	0.08	60/14	33/6	0.64
LDH, <450/≥450 IU/L	42/6	20/9	0.04 *	42/10	20/5	0.93
Hb, ≥12/<12 g/L	33/36	11/32	0.01 *	34/39	10/29	0.03 *
Albumin, ≥35/<35 g/L	35/35	9/34	0.002 *	31/43	13/26	0.37

Marks an association reaching statistical significance (p<0.05).